• Celyad Oncology: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007) Business Wire Fri, 14 Nov 2025 18:00:00 GMT
• maxion therapeutics appoints dr. david gilham as chief business officer for antibody-based therapeutics geneonline.com Fri, 03 Oct 2025 06:36:43 GMT
• celyad oncology to sell belgian research facility for eur3 million 富途牛牛 Wed, 01 Oct 2025 19:27:19 GMT
• celyad oncology to sell belgian research facility for eur3 million 富途牛牛 Tue, 30 Sep 2025 07:00:00 GMT
• €3m research facility sale: celyad oncology extends cash runway through q3 2026 in strategic move Stock Titan Mon, 29 Sep 2025 16:30:00 GMT
• celyad oncology announces research facility divestiture Business Wire Mon, 29 Sep 2025 07:00:00 GMT
• celyad oncology to sell belgian research facility for eur3 million 富途牛牛 Mon, 29 Sep 2025 07:00:00 GMT
• celyad oncology reports first half year 2025 financial results Business Wire Thu, 25 Sep 2025 07:00:00 GMT
• cash position drops to €0.8m: celyad oncology reports increased r&d investment in cancer research Stock Titan Thu, 25 Sep 2025 07:00:00 GMT
• celyad oncology sa - publication of a transparency notification received from fortress investment group llc MarketScreener Fri, 12 Sep 2025 07:00:00 GMT
• 34.1m voting rights: fortress investment's control of biotech celyad oncology dips below key 60% threshold Stock Titan Thu, 11 Sep 2025 16:30:00 GMT
• celyad oncology sa: publication of a transparency notification received from fortress investment group llc (article 14 §1 of the l... Yahoo Finance Thu, 11 Sep 2025 07:00:00 GMT
• celyad oncology sa: information on the total number of voting rights and shares (article 15 of the law of 2 may 2007) Business Wire Thu, 04 Sep 2025 07:00:00 GMT
• 57.5 million voting rights: celyad oncology announces major share structure update with double rights Stock Titan Thu, 04 Sep 2025 07:00:00 GMT
• celyad oncology’s share structure and voting rights: implications for shareholder influence and corporate control AInvest Thu, 04 Sep 2025 05:11:29 GMT
• Colorectal Cancer Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies The Globe and Mail Mon, 01 Sep 2025 07:00:00 GMT
• Celyad Oncology Announces Discontinuation of R&D Activities Business Wire Tue, 26 Aug 2025 07:00:00 GMT
• Incannex’s stock rallies on anxiety disorder data; Appia Bio closes its doors Endpoints News Tue, 26 Aug 2025 07:00:00 GMT
• celyad oncology announces discontinuation of r&d activities Yahoo Finance Mon, 25 Aug 2025 07:00:00 GMT
• celyad oncology sa: publication of a transparency notification received from fortress investment group llc Business Wire Wed, 13 Aug 2025 07:00:00 GMT
• fortress investment takes majority control of celyad oncology through $32.7m share acquisition Stock Titan Wed, 13 Aug 2025 07:00:00 GMT
• car t-cell therapy market to explode 1200%+ to $35.9 billion, forecast to 2032 newstrail.com Wed, 13 Aug 2025 07:00:00 GMT
• celyad oncology sa announces capital increase and update on total number of voting rights and shares AInvest Thu, 07 Aug 2025 16:36:23 GMT
• celyad oncology sa: information on the total number of voting rights and shares (article 15 of the law of 2 may 2007) Yahoo Finance Thu, 07 Aug 2025 07:00:00 GMT
• fortress investment group takes major stake in celyad oncology with 3.3m share investment Stock Titan Thu, 07 Aug 2025 07:00:00 GMT
• colorectal cancer pipeline outlook report 2025: key 195+ companies and breakthrough therapies shaping the future landscape Menafn Mon, 04 Aug 2025 07:07:12 GMT
• xtl biopharmaceuticals approves key resolutions at shareholder meeting AInvest Tue, 29 Jul 2025 07:00:00 GMT
• Celyad Oncology Announces €1 Million Private Placement Business Wire Mon, 28 Jul 2025 07:00:00 GMT
• celyad oncology just secured €1m investment as fortress set to control 58.5% stake Stock Titan Mon, 28 Jul 2025 07:00:00 GMT
• arbutus regains rights to hepatitis b asset in china; forte’s $75m offering Endpoints News Wed, 25 Jun 2025 07:00:00 GMT
• fortress biotech shares fall 1.68% intraday as celyad oncology reviews strategic alternatives. AInvest Wed, 25 Jun 2025 07:00:00 GMT
• celyad oncology explores strategic alternatives amid cash concerns by investing.com Investing.com Australia Wed, 25 Jun 2025 02:51:09 GMT
• Celyad Oncology explores strategic alternatives amid cash concerns Investing.com Tue, 24 Jun 2025 07:00:00 GMT
• metastatic colorectal cancer market poised for expansion across the 7mm during the forecast period (2025-2034) as breakthrough the... PR Newswire Wed, 23 Apr 2025 07:00:00 GMT
• celyad oncology reports 2024 financial results and advances in car t-cell therapies MSN Sat, 05 Apr 2025 12:46:03 GMT
• celyad oncology reports 2024 financial results and advances in car t-cell therapies TipRanks Fri, 04 Apr 2025 07:00:00 GMT
• celyad oncology reports full year 2024 financial results and recent business highlights Business Wire Wed, 02 Apr 2025 07:00:00 GMT
• celyad oncology slashes cash burn 82% while pushing revolutionary cancer tech forward Stock Titan Wed, 02 Apr 2025 07:00:00 GMT
• three's a crowd as another kite exec hits the exit; surfing tough waters, celyad oncology picks up new ceo Endpoints News Sat, 29 Mar 2025 07:00:00 GMT
• car t-cell therapy market size to reach 27.5 billion by 2033 owing to rising awareness and favourable reimbursement policies says ... PR Newswire UK Wed, 26 Mar 2025 07:00:00 GMT
• tune’s ceo search ends as john mchutchison takes top spot; more from pfizer’s leadership makeover Endpoints News Fri, 07 Mar 2025 08:00:00 GMT
• celyad oncology announces the publication of the preclinical and clinical data of cyad-211 providing proof-of-concept of its mirna... Business Wire Tue, 18 Feb 2025 08:00:00 GMT
• groundbreaking cancer treatment success: celyad's new car t-cell therapy shows zero gvhd cases in multiple myeloma trial Stock Titan Tue, 18 Feb 2025 08:00:00 GMT
• celyad oncology announces the publication of the preclinical and clinical data of cyad-211 providing proof-of-concept of its mirna... Business Wire Mon, 17 Feb 2025 08:00:00 GMT
• autologous cell therapy market is booming worldwide 2025-2032 | openPR Wed, 12 Feb 2025 03:53:00 GMT
• clyyf (celyad oncology) enterprise value : $17.61 mil (as of jan. 18, 2025) GuruFocus.com Sat, 18 Jan 2025 07:38:57 GMT
• Exclusive: Bucking gene editing downturn, Tune raises $175M to bring epigenetic editing to clinic Endpoints News Sun, 12 Jan 2025 08:00:00 GMT
• 100 cell and gene therapy leaders to watch in 2025 Drug Discovery & Development Fri, 20 Dec 2024 08:00:00 GMT
• top daily losses: us stocks posting the largest losses today uk.finance.yahoo.com Mon, 16 Dec 2024 08:19:49 GMT
• allogeneic t cell therapies market report, 2024-2028 & 2033 GlobeNewswire Thu, 12 Dec 2024 08:00:00 GMT
• Adoptive Cell Therapy Market Size to hit $23,440.7 Million by 2030, Coherent Market Insights BioSpace Tue, 26 Nov 2024 08:00:00 GMT
• companies get creative with multi-targeted cars at sitc, ash BioCentury Thu, 21 Nov 2024 08:00:00 GMT
• cancer cell market is booming with strong growth prospects 2024-2031 | kite pharma, cellectis, celyad oncology EIN News Wed, 23 Oct 2024 06:58:00 GMT
• celyad oncology to present at the 2024 sitc annual meeting Business Wire Mon, 07 Oct 2024 07:00:00 GMT
• state of new jersey common pension fund d has $3.31 million stock holdings in caesars entertainment, inc. (nasdaq:czr) Defense World Wed, 18 Sep 2024 10:05:31 GMT
• another delaware publicly traded company proposes a nevada move The National Law Review Tue, 17 Sep 2024 14:28:31 GMT
• caesars entertainment inc’s latest rating changes from various analysts Knox Daily Tue, 17 Sep 2024 10:25:06 GMT
• Belgium: Kane to take up CEO role at Celyad Oncology in October Investors in Healthcare Tue, 17 Sep 2024 07:00:00 GMT
• daiwa securities group inc. grows position in caesars entertainment, inc. (nasdaq:czr) Defense World Mon, 16 Sep 2024 09:54:22 GMT
• choreo llc purchases 6,289 shares of caesars entertainment, inc. (nasdaq:czr) Defense World Mon, 16 Sep 2024 08:49:16 GMT
• celyad oncology announces appointment of matt kane as chief executive officer Stock Titan Mon, 16 Sep 2024 07:00:00 GMT
• colorectal cancer treatment drugs, pipeline insights, and companies 2024 openPR Mon, 16 Sep 2024 03:46:00 GMT
• caesars entertainment, inc. (nasdaq:czr) shares bought by royal london asset management ltd. Defense World Sun, 15 Sep 2024 08:19:08 GMT
• celyad oncology reports first half year 2024 financial results and recent business highlights Business Wire Fri, 13 Sep 2024 07:00:00 GMT
• wedbush securities inc. invests $731,000 in caesars entertainment, inc. (nasdaq:czr) Defense World Thu, 12 Sep 2024 13:47:30 GMT
• ashton thomas private wealth llc increases stock holdings in caesars entertainment, inc. (nasdaq:czr) Defense World Thu, 12 Sep 2024 11:10:53 GMT
• autologous cell therapy products market industry trends, share, size and forecast report (2024-2034) Handheld Pipette Controller ... Mon, 09 Sep 2024 23:10:22 GMT
• autologous cell therapy products market size, innovations driving market evolution (2024-2034) Handheld Pipette Controller ... Mon, 09 Sep 2024 23:05:12 GMT
• colorectal cancer treatment drugs, clinical trials, and companies 2024 openPR Mon, 09 Sep 2024 05:40:00 GMT
• car-t cell funding market size, share, global trends and GlobeNewswire Mon, 26 Aug 2024 07:00:00 GMT
• idh inhibitor market to exhibit significant growth rate during the study period (2020–2034) | delveinsight GlobeNewswire Mon, 29 Jul 2024 07:00:00 GMT
• car t-cell therapy market size is set to grow by usd 3.02 billion from 2024-2028, growing awareness regarding car t-cell therapy t... The Malaysian Reserve Sat, 06 Jul 2024 07:00:00 GMT
• car t-cell therapy market size is set to grow by usd 3.02 billion from 2024-2028, growing awareness regarding car t-cell therapy t... PR Newswire Fri, 05 Jul 2024 07:00:00 GMT
• engineering strategies to safely drive car t-cells into the future Frontiers Wed, 19 Jun 2024 04:38:19 GMT
• celyad oncology provides fourth quarter 2023 business update and 2024 outlook br.ADVFN.com Thu, 30 May 2024 12:15:55 GMT
• cellistic and celyad oncology announce gmp cell therapy manufacturing operations transaction Quantisnow Thu, 30 May 2024 10:36:26 GMT
• aacr annual meeting 2018 - cyad-101-002, immuno-oncology The Pharma Letter Sun, 12 May 2024 08:19:14 GMT
• aacr annual meeting 2018 - cyad-101-002, biotechnology The Pharma Letter Sat, 11 May 2024 20:11:03 GMT
• ers international congress 2016 - cyad-101-002, biotechnology The Pharma Letter Tue, 07 May 2024 14:52:52 GMT
• celyad oncology reports full year 2023 financial results and recent business highlights Yahoo Finance Thu, 04 Apr 2024 07:00:00 GMT
• relapsed/refractory acute myeloid leukemia pipeline outlook report 2024 openPR Thu, 04 Apr 2024 07:00:00 GMT
• celyad oncology reports full year 2023 financial results and recent business highlights Yahoo Finance Wed, 03 Apr 2024 07:00:00 GMT
• global gmp cell therapy consumables market projected to GlobeNewswire Thu, 28 Mar 2024 07:00:00 GMT
• a cure for cancer? how car-t cell therapy is revolutionizing oncology Labiotech.eu Mon, 25 Mar 2024 07:00:00 GMT
• car t-cell therapy market cagr of 36.2%, bridging gaps strategies for identifying and targeting your audience through segmentation... Taiwan News Thu, 29 Feb 2024 08:00:00 GMT
• celyad oncology receives approximately eur 9.8m in private placement commitments from historical shareholders br.ADVFN.com Mon, 26 Feb 2024 19:25:22 GMT
• chutes & ladders—exscientia ceo out after 'inappropriate' relationships with 2 staffers Fierce Biotech Fri, 16 Feb 2024 08:00:00 GMT
• stromacare appoints georges rawadi as ceo | the pharmaletter The Pharma Letter Tue, 13 Feb 2024 08:00:00 GMT
• celyad oncology announces intention to terminate sec reporting obligations PharmiWeb.com Fri, 09 Feb 2024 08:00:00 GMT
• celyad oncology announces intention to terminate sec reporting obligations Yahoo Finance Thu, 08 Feb 2024 08:00:00 GMT
• celyad oncology sa to voluntarily halt sec reporting obligations BNN Breaking Thu, 08 Feb 2024 08:00:00 GMT
• relapsing/refractory multiple myeloma market to observe stupendous growth by 2032, estimates delveinsight | leading companies - br... PR Newswire Thu, 25 Jan 2024 08:00:00 GMT
• celyad oncology provides q4 2023 business update and 2024 outlook Medical Buyer Wed, 17 Jan 2024 08:00:00 GMT
• celyad oncology provides fourth quarter 2023 business update and 2024 outlook GlobeNewswire Tue, 16 Jan 2024 08:00:00 GMT
• publication of a transparency notification received from GlobeNewswire Wed, 20 Dec 2023 08:00:00 GMT
• celyad oncology sa: publication of a transparency notification received from fortress investment group llc Yahoo Finance Wed, 20 Dec 2023 08:00:00 GMT
• celyad oncology: information on the total number of voting rights and shares (article 15 of the law of 2 may 2007) PharmiWeb.com Sat, 16 Dec 2023 08:00:00 GMT
• information on the total number of voting rights and shares (article 15 of the law of 2 may 2007) GlobeNewswire Fri, 15 Dec 2023 08:00:00 GMT
• celyad oncology: information on the total number of voting rights and shares (article 15 of the law of 2 may 2007) Yahoo Finance Fri, 15 Dec 2023 08:00:00 GMT
• celyad oncology ceo stapt op wegens persoonlijke redenen Marketscreener NL Mon, 04 Dec 2023 16:05:06 GMT
• celyad oncology sa annonce un changement de direction Zonebourse.com Mon, 04 Dec 2023 13:34:00 GMT
• celyad oncology sa kondigt directiewisseling aan -04 december ... Marketscreener NL Mon, 04 Dec 2023 13:34:00 GMT
• ucb en vedette | biotalys grimpe encore | avis de brokers sur gbl ... L'Echo Mon, 04 Dec 2023 11:48:45 GMT
• celyad oncology: démission du pdg georges rawadi -le 04 ... Zonebourse.com Mon, 04 Dec 2023 08:56:04 GMT
• nouveau fan pour proximus | mithra bondit | avis de brokers sur ... L'Echo Mon, 04 Dec 2023 08:25:28 GMT
• celyad announces management change | markets - medicine hat newsmedicine hat news FinancialContent Mon, 04 Dec 2023 08:00:00 GMT
• celyad oncology : announces management change -december 01 ... Marketscreener.com Fri, 01 Dec 2023 21:10:13 GMT
• nouveau fan pour proximus | mithra bondit | avis de brokers sur ... L'Echo Fri, 01 Dec 2023 11:59:59 GMT
• publication of a transparency notification received from tolefi sa (article 14 §1 of the law of 2 may 2007) GlobeNewswire Fri, 01 Dec 2023 08:00:00 GMT
• publication d’une notification de transparence reçue de tolefi sa Boursorama Thu, 30 Nov 2023 21:01:00 GMT
• publication of a transparency notification received from tolefi sa (article 14 §1 of the law of 2 may 2007) celyad oncology sa wallstreet:online Thu, 30 Nov 2023 21:01:00 GMT
• celyad oncology sa: publication of a transparency notification received from tolefi sa (article 14 §1 of the law of 2 may 2007) Business Wire Thu, 30 Nov 2023 08:00:00 GMT
• publication of a transparency notification received from fortress investment group llc (article 14 §1 of the law of 2 may 2007) Yahoo Tue, 21 Nov 2023 08:00:00 GMT
• celyad oncology sa: publication of a transparency notification received from fortress investment group llc Business Wire Tue, 21 Nov 2023 08:00:00 GMT
• swiss cancer vaccine biotech nouscom raises $72m series c for phii trials Endpoints News Tue, 14 Nov 2023 08:00:00 GMT
• celyad oncology: information on the total number of voting rights and shares (article 15 of the law of 2 may 2007) Business Wire Tue, 14 Nov 2023 08:00:00 GMT
• information relative au nombre total de droits de vote et d’actions Boursorama Tue, 14 Nov 2023 08:00:00 GMT
• celyad oncology reports third quarter 2023 financial results and recent business highlights Yahoo Finance Thu, 09 Nov 2023 08:00:00 GMT
• celyad oncology: trésorerie de 2,3 millions, visibilité jusqu'au 1er ... Capital.fr Thu, 09 Nov 2023 08:00:00 GMT
• wall street clôture dans le rouge, powell casse l'optimisme des ... L'Echo Thu, 09 Nov 2023 08:00:00 GMT
• celyad oncology reports third quarter 2023 financial results and recent business highlights Yahoo Finance Wed, 08 Nov 2023 08:00:00 GMT
• alberta government tables bill to strengthen opioid cost-recovery ... Yahoo Canada Finance Tue, 31 Oct 2023 07:00:00 GMT
• sopra steria chute après avoir présenté une croissance organique ... Option Finance Fri, 27 Oct 2023 07:00:00 GMT
• clinical holds for cell and gene therapy trials: risks, impact, and lessons learned ScienceDirect.com Tue, 24 Oct 2023 16:14:37 GMT
Celyad Oncology SA(NASDAQ:CYAD) 
Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor-T (CAR-T) cell-based therapies for the treatment of cancer. Its lead product candidates includes CYAD-101, an allogeneic CAR-T candidate that is in Phase 1 clinical t...
Website: http://www.celyad.com
Founded: 2004
Full Time Employees: 105
Sector: Healthcare
Industry: Biotechnology